# NCT03302234 (NCT03302234)

> Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03302234
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Pembrolizumab; Ipilimumab; Placebo
- Enrollment: 568
- Primary outcome: Overall Survival (OS)
- Primary outcome: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR)

## Commentary we found

- X threads: 5
- Podcasts: 3
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03302234

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03302234", "email": "<work email>"}; the inbox owner confirms by the emailed link.